Home | Back to newsletter main page

Bookmark and Share
Case Comprehensive Cancer Center Newsletter

August 5, 2013

gersonMESSAGE FROM THE DIRECTOR

Stan Gerson, MD
Director, Case CCC

Sequester Impact on Biomedical Research - Every Voice Counts

The effects of the sequester on the research community are becoming increasingly apparent, so we must take the opportunity to speak up and remind our political leaders that the reduced funding is having detrimental effects on biomedical research progress.

Last week, an open letter from 185 university leaders, including CWRU President Barbara R. Snyder, in the Washington, DC newspaper Politico, urged President Barack Obama and Congress to restore funding for research and education. Today, a Plain Dealer article highlighted the research of Dr. Yu-Chung Yang, a recent recipient of a Bridge Grant from the American Society of Hematology. Concerned that reduced NIH funding means reduced progress in cancer research, ASH is now offering funds to researchers whose work is considered promising, but was not scored well enough to secure funding from the NIH. As Dr. Yang pointed out in the article, it is not just her research that will suffer, but also that of the future generation of scientists and researchers.

The above examples are but a step in the right direction. Calling attention to the importance of reinstating funding levels for the NIH is the responsibility of every member of the cancer center and its community. Please take the time to voice your concerns and personal examples of just how the sequester will have a negative effect on your research progress. Write a short note to members of the Ohio caucus to reiterate how important this issue is to each of us, to our region, and to our national priorities.

Contact Information for Ohio Senators and Representatives:
Sen. Robert Portman
Sen. Sherrod Brown
Rep. Steve Chabot (District 1)
Rep. Brad Wenstrup (District 2)
Rep. Joyce Beatty (District 3)
Rep. Jim Jordan (District 4)
Rep. Bob Latta (District 5)
Rep. Bill Johnson (District 6)
Rep. Bob Gibbs (District 7)
Rep. John Boehner (District 8
Rep. Marcy Kaptur (District 9)
Rep. Michael Turner (District 10)
Rep. Marcia Fudge (District 11)
Rep. Pat Tiberi (District 12)
Rep. Tim Ryan (District 13)
Rep. David Joyce (District 14)
Rep. Steve Stivers (District 15)
Rep. Jim Renacci (District 16)


CASE CCC IN THE NEWS

CWRU Researcher Benefits from National Grant Program Created to Protect Hematology Work from Budget Cuts (video)
The Plain Dealer - Aug 5, 2013
The American Society of Hematology is was to award a second round of ASH Bridge Grants this summer to scientists who have hit a roadblock in getting funding for their research. In April, Yu-Chung Yang, a professor in the department of biochemistry at Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center, was one of 17 scientists (out of 45 applicants, all members of the society), awarded $100,000 as part of the first round of the awards, conceived last year.

University Hospitals Seidman Cancer Center expands to Parma hospital
The Plain Dealer - Aug 1, 2013
University Hospitals Seidman Cancer Center opened a new site today at Parma Community General Hospital, which will now provide Parma patients access to advanced cancer therapy and clinical trials...Dr. Stan Gerson, director of the UH Seidman Cancer Center, said in an interview that this kind of coordinated care is "dramatically different" from how cancer treatment normally works in a community setting. Instead of seeing one physician at a time, patients will benefit from multiple experts from a variety of disciplines early on.

NCI Panel: Stop Calling Low-Risk Lesions 'Cancer'
MedScape - Jul 30, 2013
"I agree with the premise of the article, and I agree in general with their suggestions," said Mikkael Sekeres, MD, director of the leukemia program at the Cleveland Clinic in Ohio, and chair of the US Food and Drug Administration Oncology Drug Advisory Committee, who was asked by Medscape Medical News for comment. Low-risk myelodysplastic syndrome, which is classified by the World Health Organization as a neoplasma, is another example of a condition in need of a nomenclature adjustment, he said. Patients are often diagnosed with myelodysplastic syndrome as a result of a routine blood test taken by the primary care doctor; as a result, they live with a diagnosis of cancer but typically receive no treatment because the condition is low risk and without symptoms, Dr. Sekeres explained. "This is a very similar situation but is less well known" than the scenarios involving prostate-specific antigen testing or ductal carcinoma in situ found with mammography, he noted.


ANNOUNCEMENTS

Schiemann and Carlin Attempt to Further Understand Triple Negative Breast Cancers; Research Highlighted in Cancer Research Breaking Advances

Triple-negative breast cancers (TNBCs) are an unusually aggressive and metastatic form of breast cancer for which there are currently no FDA-approved treatments. Interestingly, TNBCs typically express robust levels of epidermal growth factor receptor (EGFR), whose clinical targeting has proven to be unremarkable for reasons that remain mysterious. A collaborative paper published in the Journal of Biological Chemistry by the Carlin and Schiemann laboratories identified an innovative mechanism that partially explains the ineffectiveness of EGFR inhibitors to alleviate TNBCs. Using a novel EGFR-driven model of TNBC development and metastatic progression, the authors found that primary tumor growth depends upon their ability to stimulate the proto-oncogene Stat3, an event that transpired through a Src-dependent EGFR signaling axis and could be inactivated by administration of EGFR antagonists. Importantly, inducing TNBCs to undergo an epithelial-mesenchymal transition (EMT) program not only enhanced their metastatic aggressiveness, but also switched the manner through which they activate Stat3 during metastasis. Indeed, post-EMT TNBCs relied upon fibronectin present in the tumor microenvironment to activate a β1 integrin:FAK/Pyk2:JAK2 signaling axis operant in stimulating Stat3 and their metastatic outgrowth. Unlike their pre-EMT counterparts, post-EMT TNBCs were insensitive to EGFR antagonists and instead acquired sensitivity to JAK2 and Stat3 inhibitors. Collectively, this study identified an important mechanism whereby TNBCs exploit EMT programs to bypass growth factor signaling pathways that are essential for tumor initiation in favor of tumor microenvironmental signals critical for their metastatic progression. Nikolas Balanis, Michael Wendt, Barbara Schiemann, John Wang, Bill Schiemann, and Cathleen Carlin contributed to this publication.

Team from the Center for Computational Imaging and Personalized Diagnostics Receives Coulter Translational Award

Drs. Pallavi Tiwari and Anant Madabhushi have been awarded a Coulter Translational Award for their project, NeuroRadVision: Image based risk assessment for presence of recurrent tumor or radiation effects on MRI. The project involves developing novel image analytic approaches to distinguish radiation effects from recurrent brain tumors, a significant clinical problem in the management of brain tumor patients. Clinical collaborators on this project include Drs. Lisa Rogers, Leo Wolansky, and Andrew Sloan.


FUNDING OPPORTUNITIES

Avon Safety Net Program

The Avon Safety Net Program supports institutions and organizations that have traditionally cared for uninsured, at-risk, low-income and minority patients to further our commitment of enabling medically underserved women and men to access post-screening diagnostics and care.
LOI Deadline: September 12
Application Deadline: October 24

Leukemia & Lymphoma Society (LLS) Career Development Program (CDP)

The Leukemia & Lymphoma Society Career Development Program offers the opportunity for researchers to take part in basic, clinical or translational research to help treat leukemia, lymphoma and myeloma.

  • Scholar: Open to highly qualified investigators who have shown a capacity for independent, sustained original investigation in the field of leukemia, lymphoma and myeloma. Applicants should hold an independent faculty-level or equivalent position and have obtained substantial support for your research from a national agency.
    LOI Deadline: October 1
    Application Deadline: October 15
  • Scholar in Clinical Research: Open to highly qualified investigators who hold an independent faculty-level appointment and are conducting original, independent applied research, often involving early-stage clinical trials that will advance the prevention, diagnosis or treatment of hematologic malignancies. Applicants are expected to have concomitant support for their research from another source or agency.
    LOI Deadline: October 1
    Application Deadline: October 15
  • Special Fellow: Open to qualified investigators who have completed a minimum of two years of postdoctoral research training and are continuing to conduct research under the research sponsor's direction, under the assumption that applicants will begin to transition to an independent research program.
    LOI Deadline: October 1
    Application Deadline: October 15
  • Special Fellow in Clinical Research: Open to researchers that hold a PhD, MD or equivalent degree and have completed at least two years of clinical hematology, oncology, hematology/oncology or hematopathology training or postdoctoral research training in a clinical discipline (such as cytogenetics or molecular pathology). Applicants must show evidence that their career focus will be on preventing, diagnosing or treating leukemia, lymphoma or myeloma.
    LOI Deadline: October 1
    Application Deadline: October 15
  • Fellow: Open to promising investigators with less than two years of postdoctoral research training. This award encourages researchers to embark on an academic career involving clinical or fundamental research in, or related to, leukemia, lymphoma or myeloma under a research sponsor's direction.
    LOI Deadline: October 1
    Application Deadline: October 15

EVENTS

calendar

August 5

Special Chalk Talk: Division of Hematology and Oncology
Hisashi Tanaka MD, PhD
Assistant Professor, Molecular Genetics
CWRU/Cleveland Clinic
Topic: Gene Amplification Mechanisms as Targets of Cancer Diagnosis and Therapy
9 am WRB 2-136

Immunology Invited Speaker Seminar Series
Peter Heeger, MD
Professor, Medicine
Mt. Sinai Hospital
Topic: Bridging Innate and Adaptive T Cell Immunity Through Complement
12 pm NC1-202 Cleveland Clinic

Special Seminar
Wanfeng Yu, PhD
Research Associate, Eng lab, Genomic Medicine Institute
Cleveland Clinic
Topic: Regulation of SDHD and PTEN Subcellular Trafficking and Tumor Suppression Function
12:30 pm NE1-205 Cleveland Clinic


August 6

DNA Damage/Repair Speaker Series
Youwei Zhang, PhD
Assistant Professor, Pharmacology
CWRU
Topic: TBD
4 pm WRB 3-136


August 7

Hematology and Oncology Division Research Conference
Jakub Tolar, MD, PhD
Associate Professor, Pediatrics - Div. of Blood and Marrow Transplantation
University of Minnesota
Topic: More Than Skin Deep: Stem Cell Gene Therapy for Lethal Genodermatosis
8 am Lerner Tower B-151


August 8

 


August 9

Cancer Center Research in Progress will resume in September

Taussig Cancer Institute Grand Rounds will resume in September

Hematology and Oncology Fellows Conference
Topic: TBD
8 am Wearn 137

 

 

Case CCC Calendar

LRI Calendar


UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS

 

ADDITIONAL UPCOMING SEMINARS & EVENTS

 

MSC 2013: Adult Stem Cell Therapy & Regenerative Medicine
August 19-21
Cleveland Marriott Downtown at Key Center
Details

Molecular Genetics Guest Speaker
August 28
Myron R. Szewczuk, PhD
Department of Biomedical and Molecular Sciences
Queen's University
Topic: Neu1 Sialidase and Matrix Metalloproteinase-9 Cross-talk Regulates Nucleic Acid-induced Endosomal TOLL-like Receptor-7 and -9 Activation, Cellular Signaling and Pro-inflammatory Responses
9:30 am NE1-205 Cleveland Clinic

National GvHD Health Symposium
November 1
Embassy Suites Cleveland-Rockside
Details


PREVIOUSLY ANNOUNCED OPPORTUNITIES

American Cancer Society Institutional Research Grant (IRG) Awards
LOI Deadline: August 12
Application Deadline: September 13

Uniting Against Lung Cancer Legacy Program
Deadline: August 14

PCRP Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award
LOI Deadline: August 15
Application Deadline: September 5

PCRP Physician Research Training Award
LOI Deadline: August 15
Application Deadline: September 5

PCRP Postdoctoral Training Award
LOI Deadline: August 15
Application Deadline: September 5

Prevent Cancer Foundation Grants and Fellowships
Deadline: August 21

Avon Breast Health Outreach Program
Deadline: August 23

American Gastroenterological Association Funderburg Research Award in Gastric Cancer
Deadline: August 30

Susan G. Komen Career Catalyst Research Grants – Basic and Translational Research
Pre-Application Deadline: September 5
Full Application Deadline: December 5

Susan G. Komen Career Catalyst Research Grants – Clinical Research
Pre-Application Deadline: September 5
Full Application Deadline: December 5

Susan G. Komen Postdoctoral Fellowship Grants – Basic and Translational Research
Pre-Application Deadline: September 5
Full Application Deadline: December 5

Susan G. Komen Postdoctoral Fellowship Grants – Clinical Research
Pre-Application Deadline: September 5
Full Application Deadline: December 5

Susan G. Komen Graduate Training in Disparities Research (GTDR)
Pre-Application Deadline: September 5
Full Application Deadline: December 5

AACR-CRI Lloyd J. Old Award in Cancer Immunology
Nomination Deadline: September 6

Pezcoller Foundation–AACR International Award for Cancer Research
Nomination Deadline: September 12

Alex's Lemonade Stand Foundation 'A' Award
Deadline: September 16

PCRP Health Disparity Research Award
LOI Deadline: September 18
Application Deadline: October 9

PCRP Clinical Consortium Award
LOI Deadline: September 18
Application Deadline: October 9

PCRP Prostate Cancer Pathology Resource Network (PCPRN or Network) Award
LOI Deadline: September 18
Application Deadline: October 9

PCRP Population Science Impact Award
LOI Deadline: September 18
Application Deadline: October 9

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
Nomination Deadline: September 19

AACR Princess Takamatsu Memorial Lectureship
Nomination Deadline: September 19

AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
Nomination Deadline: September 26

Szent-Györgyi Prize for Progress in Cancer Research
Deadline: September 30

AACR Award for Outstanding Achievement in Chemistry in Cancer Research
Nomination Deadline: October 3

AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship
Nomination Deadline: October 3

AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship
Nomination Deadline: October 3

AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
Nomination Deadline: October 10

AACR Richard and Hinda Rosenthal Memorial Award
Nomination Deadline: October 10

RFA: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families
Deadline: October 15

AACR G.H.A. Clowes Memorial Award
Nomination Deadline: October 17

Foundation for Women's Cancer Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher
Deadline: October 23

Foundation for Women's Cancer Dr. John L. Lewis, Jr./William F. O'Connor Foundation Research Prize
Deadline: October 23

Foundation for Women's Cancer Perlman Family CARE Lynch Syndrome Research Prize
Deadline: October 23

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

Case CCC Protocol Specific Research Support (PSRS)
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

International Waldenstrom's Macroglobulinemia Foundation (IWMF) Research Grant Program
Application Deadline: Open

SAIC-Frederick Support of the Cancer Genome Atlas Program
Application Deadline: Open

Solving Kids' Cancer Therapeutic Development Initiative
Application Deadline: Open


NIH BULLETIN – Notices and Funding Opportunities

Pilot studies in Pancreatic Cancer (R03)(PA-11-298)

Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (UM1)(PAR-11-167)

Identifying Non-coding RNA Targets for Early Detection of Cancer (R21)(PA-12-214)

National Cancer Institute (NCI) Cancer Education and Career Development Program (R25)(PAR-10-165)

Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21)(PA-13-288)

Research Project Grant (Parent R01)(PA-13-302)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216.844.8317 phone
216.844.7832 fax
gillian.irwin@case.edu

HELP US HELP YOU!

If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to gillian.irwin@case.edu.